An appreciation of robert turner

Diabetes

Volumn 57, Issue 11, 2008, Pages 2918-2921

  O'Rahilly, Stephen ^a   Weir, Gordon C ^b   Matthews, David R ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL STUDENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; POSTDOCTORAL EDUCATION; PRIORITY JOURNAL; SCIENTIST; THEORETICAL MODEL; ARTICLE; BLOOD; HISTORY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; UNITED KINGDOM;

BIOMEDICAL RESEARCH; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HISTORY, 20TH CENTURY;

EID: 58149350188     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1644     Document Type: Note

References (31)

1. Turner RC, Grayburn JA, Newman GB, Nabarro JD: Measurement of the insulin delivery rate in man. J Clin Endocrinol Metab 33:279-286, 1971
2. Turner RC, Johnson PC: Suppression of insulin release by fish-insulin- induced hypoglycaemia: with reference to the diagnosis of insulinomas. Lancet 1:1483-1485, 1973
3. Albano JD, Ekins RP, Maritz G, Turner RC: A sensitive, precise radioim- munoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol (Copenh) 70:487-509, 1972
4. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 28:1086-1096, 1979
5. Lang DA, Matthews DR, Peto J, Turner RC: Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med 301:1023-1027, 1979
6. Matthews DR, Naylor BA, Jones RG, Ward GM, Turner RC: Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 32:617-621, 1983
7. Matthews DR, Lang DA, Burnett MA, Turner RC: Control of pulsatile insulin secretion in man. Diabetologia 24:231-237, 1983
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
9. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG,
10. Turner RC: Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabe-tologia 28:401-411, 1985
11. O'Rahilly SP, Nugent Z, Rudenski AS, Hosker JP, Burnett MA, Darling P, Turner RC: Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet 2:360-364, 1986
12. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, Wellcome Trust Case Control Consortium (WTCCC), McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336-1341, 2007
13. Holman RR, Turner RC: Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes. Diabetes 28:227-230, 1979
14. O'Rahilly S, Turner RC, Matthews DR: Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225-1230, 1988
15. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
16. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
17. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
18. Clark A, Cooper GJ, Lewis CE, Morris JF, Willis AC, Reid KB, Turner RC: Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 2:231-234, 1987
19. Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, O'Rahilly S, Watkins PJ, Wainscoat JS: Linkage of type 2 diabetes to the glucokinase gene. Lancet 339:1307-1310, 1992
20. Stoffel M, Patel P, Lo YM, Hattersley AT, Lucassen AM, Page R, Bell JI, BellGI, Turner RC, Wainscoat JS: Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes. Nat Genet 2:153-156, 1992
21. Turner RC, Oakley NW, Nabarro JD: Control of basal insulin secretion, with special reference to the diagnosis of insulinomas. Br Med J2:132-135, 1971
22. Turner RC: The diagnosis of insulinomas and other causes of fasting hypoglycemia. Horm Metab Res Suppl 6:40-45, 1976
23. Alberti KG, Hockaday TD, Turner RC: Small doses of intramuscular insulin in the treatment of diabetic "coma." Lancet 2:515-522, 1973
24. UKPDS Group: UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877-890, 1991
25. UKPDS Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-854, 1998
26. UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
27. UKPDS Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
28. UKPDS Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-726, 1998
29. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 321:412-419, 2000
30. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (England) 321:405-412, 2000
31. Turner R, Blackwood R: Lecture Notes on History Taking and Examination. Oxford, U.K., Blackwell Scientific, 1991